4OTI

Crystal Structure of PRK1 Catalytic Domain in Complex with Tofacitinib

Summary for 4OTI

Entry DOI	10.2210/pdb4oti/pdb
Related	4OTD 4OTG 4OTH
Descriptor	Serine/threonine-protein kinase N1, 3-{(3R,4R)-4-methyl-3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl}-3-oxopropanenitrile (3 entities in total)
Functional Keywords	prk1, pkn1, protein kinase c related kinase 1, kinase, protein kinase, atp binding, phosphorylation, transferase-transferase inhibitor complex, transferase/transferase inhibitor
Biological source	Homo sapiens (human)
Cellular location	Cytoplasm : Q16512
Total number of polymer chains	1
Total formula weight	38653.87
Authors	Chamberlain, P.P.,Delker, S.,Pagarigan, B.,Mahmoudi, A.,Jackson, P.,Abbassian, M.,Muir, J.,Raheja, N.,Cathers, B. (deposition date: 2014-02-13, release date: 2014-08-27, Last modification date: 2018-01-24)
Primary citation	Chamberlain, P.,Delker, S.,Pagarigan, B.,Mahmoudi, A.,Jackson, P.,Abbasian, M.,Muir, J.,Raheja, N.,Cathers, B. Crystal Structures of PRK1 in Complex with the Clinical Compounds Lestaurtinib and Tofacitinib Reveal Ligand Induced Conformational Changes. Plos One, 9:e103638-e103638, 2014 Cited by PubMed: 25111382 DOI: 10.1371/journal.pone.0103638 PDB entries with the same primary citation
Experimental method	X-RAY DIFFRACTION (1.93 Å)

Structure validation